Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.

Article Details

Citation
Copy to clipboard

Parish D, Scheinfeld N

Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.

Curr Opin Investig Drugs. 2008 Feb;9(2):201-9.

PubMed ID
18246523 [ View in PubMed
]
Abstract

Forest Laboratories (following its acquisition of Cerexa Inc, a spin-out from Peninsula Pharmaceuticals Inc), under license from Takeda, is developing ceftaroline fosamil, an N-phosphono prodrug of ceftaroline, a derivative of a fourth-generation cephalosporin, for the potential treatment of methicillin-resistant Staphylococcus aureus infection. Phase III clinical trials evaluating ceftaroline fosamil for community acquired pneumonia and complicated skin and skin structure infections are underway.

DrugBank Data that Cites this Article

Drugs